Blog

Význam integrovaného testu ve screeningu Downova syndromu

06.06.2018
Authors: Springer D, Loucky J, Tesner P, Cutka D, Stejskal D, Gregor V, Zima T
Source: J Med Screen 2018 Jan 01.:969141317752533.

Abstract

Objective In the Czech Republic, over 97% of all pregnant women undergo some type of antenatal screening for Down's syndrome. In about 95% of cases with a confirmed fetal chromosomal abnormality, the pregnancy is terminated. The most commonly used test is the first trimester combined test. We investigated the impact of implementing an integrated sequential test to improve the detection of Down's syndrome pregnancies. Methods Data on the incidence of congenital defects, number of births, and affected pregnancies terminated are recorded in the National Registry of Congenital Anomalies. Anonymous data on cases of Down's syndrome diagnosed antenatally or postnatally between 2010 and 2015 in one of the large antenatal care centers were analyzed. Results There were 600 diagnoses of Down's syndrome (5.7 per 1000 births), 90% of which were made antenatally. Of antenatally detected cases, 80% were indicated for diagnostic procedure by multimarker screening results. In the multimarker screen positive group, 75% cases were first trimester positive and 25% second trimester positive (most of these had positive integrated test results). Among Down's syndrome cases indicated for antenatal diagnosis by multimarker screening results 6.25% (n = 26) were first trimester negative, and became positive after integration with the second trimester screening results. Conclusions Results from five major Czech antenatal centers confirm that an integrated sequential test would detect 80-85% of Down's syndrome fetuses in the first trimester and at least an extra 5-10% of Down's syndrome pregnancies in the second trimester of pregnancy. These are important data that should be considered in implementing the national antenatal screening program.

 

 


Mohlo by vás zajímat

Novinka
24.01.2023

Vážení klienti, rádi bychom vám oznámili, že ve dnech od 6. 2. 2023 – 10. 2. 2023  bude mít MUDr. Viktor Vik dovolenou.  

Revoluce v péči o těhotné nově v GENNET Letná
Novinka
19.01.2023

Nejvýkonnější a nejpokročilejší ultrazvukový přístroj nově pečuje o nastávající maminky na oddělení fetální medicíny na klinice GENNET Letná. Nově zde mají naši…

Inspirujte se projekty, které jsme podpořili v minulém roce. Zapojíte se také?
Novinka
18.01.2023

Jako každý rok, i v roce 2022 jsme finančně podpořili projekty, které pomáhají lidem se zdravotním hendikepem, šíří osvětu, snaží se ulehčit v náročných…

Novinka
18.01.2023

Nově pacientkám nabízíme vyšetření GERT – GENNET Endometrial Receptivity Test (GENNET test citlivosti endometria), který jsme vyvinuli v našich laboratořích.